Medical Malpractice Insurance in New York: A 2026 Physician's Guide

TL;DR. Medical malpractice insurance in New York costs more than in nearly any other state, driven by a $550+ million annual payout environment, no damage caps, and the 2½-year CPLR 214-a statute of limitations extended by Lavern's Law for cancer misdiagnoses. Admitted carriers MLMIC, EmPRO, and The Doctors Company underwrite most NY physicians, with rates varying 3–5× between Rochester and Long Island.

Coverage basics: claims-made vs occurrence

Claims-made policies, the dominant New York structure, cover claims only when both the alleged act and the claim filing occur during the active policy period. Occurrence policies respond to any incident during coverage regardless of when reported. Claims-made premiums typically run 40–60% lower in year one but require tail at roughly 200% of annual premium on termination, and NY carriers post a 89.7% direct loss ratio, the highest in the top ten states (Fiedler Deutsch / NAIC, 2023).

How claims-made works in New York

A claims-made policy has two trigger conditions that must both be satisfied for coverage to respond. First, the alleged malpractice must have occurred on or after the policy's retroactive date. Second, the patient's claim must be reported to the carrier while the policy is still active, or during an extended reporting period purchased on termination.

Premium grows each year for the first five years of a claims-made policy under what carriers call a step factor. Year one pricing typically runs at around 30% of mature premium, year two at 55%, year three at 75%, year four at 90%, and year five onward at 100%. For a physician just out of fellowship, this makes claims-made meaningfully cheaper than occurrence through the critical early-career years.

The trade-off emerges at exit. When a claims-made policy terminates, the physician is no longer insured for future reports of past care, and must either buy tail from the departing carrier or negotiate nose coverage with the next. Both cost money, and both are discussed in detail below.

Occurrence as alternative, and why NY carriers rarely quote it

Occurrence policies eliminate the tail problem because coverage attaches to the date of care, not the date of report. A 2019 occurrence policy will defend a 2025 lawsuit for a 2019 incident without any additional purchase. For a retiring physician or a specialist with a long claim-development window, this is clean.

The New York admitted market has largely stopped quoting occurrence at competitive prices. MLMIC, EmPRO, and The Doctors Company all favor claims-made as their default structure, and occurrence quotes, when issued, typically run 25–40% above the equivalent mature claims-made premium. For most NY physicians, claims-made plus disciplined tail planning is the more economic path.

The retroactive-date concept

Retroactive date is the single most important field on a claims-made policy. It defines the earliest date of a covered act. A policy with a 2018 retroactive date will cover a claim filed in 2026 for an alleged 2019 incident, provided the policy is active when the claim is reported. A policy with a 2024 retroactive date will not.

When physicians move between carriers, the new carrier's willingness to accept the prior retroactive date, referred to as continuous retro, determines whether years of past care carry forward or require separate tail purchase from the departing carrier. We return to this in the switching-carriers section.

NY admitted carriers: MLMIC, EmPRO, TDC, and the MMIP Pool

Four admitted carriers dominate New York: MLMIC (a Berkshire Hathaway subsidiary) insuring over 13,000 physicians and 3,000 dentists (MLMIC, 2024); EmPRO (formerly PRI) with $190.2M in gross written premium and an 87.9% combined ratio (Business Wire / EmPRO, 2024); The Doctors Company; and the statutory MMIP Pool for physicians declined by the voluntary market. Broker advisories report the Section 18 Excess program closed to new enrollment on December 31, 2024, a fact physicians should verify with the NY Department of Health before making coverage decisions.

MLMIC under Berkshire Hathaway

Medical Liability Mutual Insurance Company is New York's largest medical professional liability writer and has held that position for more than 45 years. It insures more than 13,000 physicians, 3,000 dentists, and dozens of hospitals and health systems across the state. Berkshire Hathaway acquired MLMIC in 2018 as part of its National Indemnity platform, which converted MLMIC from a mutual insurer to a stock insurer.

The 2018 demutualization triggered one-time distributions to policyholders of record, and New York courts have since held in the CBMS v. MLMIC line of cases that those distributions belong to the insured physician rather than the employer that paid the premium, absent a clear contractual assignment. Physicians who were employed during the relevant distribution period, whose employers still hold the dividend in escrow, should consult counsel on recovery. This is one of the most common, and most overlooked, claims in current NY physician compensation disputes.

EmPRO and The Doctors Company as competitors

EmPRO, formerly known as Physicians' Reciprocal Insurers (PRI), is New York's third-largest admitted MPL insurer. The 2024 results show $190.2M in gross written premium and an 87.9% combined ratio, indicating disciplined underwriting and sustainable pricing. EmPRO targets the same voluntary-market physician base as MLMIC but competes primarily on service responsiveness and specialty appetite rather than price.

The Doctors Company (TDC) is a physician-owned national mutual and the largest MPL writer in the United States by policyholder count. In New York, TDC's book skews toward employed physicians at hospital-affiliated groups and multi-state practices, because TDC can write consistent limits across state lines where MLMIC and EmPRO are New York-only. TDC's dividend history is also a practical consideration for long-horizon physicians.

A fourth voluntary-market name, the MLMIC Risk Retention Group or RRG vehicle, overlaps with MLMIC's admitted book for specialty placements. Most NY physicians will never interact with it directly, but brokers use it to place risks that sit just outside MLMIC's admitted appetite.

The MMIP Pool and Section 18 Excess

The New York Medical Malpractice Insurance Plan (MMIP) is the statutory market of last resort. Physicians and dental professionals declined by the voluntary market are assigned to the MMIP, which spreads the risk across all admitted NY MPL carriers by pro-rata share. Premium runs at a surcharge to voluntary-market rates, and reported reasons for assignment, typically claim frequency, disciplinary history, or uninsurable specialties, are disclosed to the assigned carrier.

Section 18 of the New York Public Health Law authorized the Excess Medical Malpractice Program, a state-funded $1M/$3M second layer that sat above a physician's primary $1.3M/$3.9M limit at no cost to eligible physicians. Multiple broker advisories report that the program closed to new enrollment as of December 31, 2024, with existing enrollees grandfathered. Physicians who relied on Section 18 for credentialing limits now need broker-sourced excess at their own cost, and the market has not yet absorbed the full substitution demand. No NY Department of Health primary source confirming the closure has been located at the time of writing, so physicians should confirm current status before making coverage decisions.

NY specialty cost table

Statewide 2026 base rates at $1M/$3M claims-made limits range from roughly $29K–$32K for Internal Medicine without surgery to approximately $170K–$200K for OB/GYN with major surgery, reflecting MLMIC and EmPRO filings. General Surgery sits in the $110K–$125K range, Orthopedic Surgery without spine at $100K–$115K, and Anesthesiology at $55K–$65K, all before territory modifiers that add 40–200% in downstate zones. These are statewide base rates only.

Statewide base rates by specialty

How territory modifier stacking works

The number a physician actually pays is the specialty base multiplied by a territory factor tied to the practice zip code. Territory factors in New York run from roughly 0.5 in Rochester and much of the Southern Tier to 1.7 or higher in Nassau and Suffolk counties, producing a spread of 3.4× on the same specialty code. Manhattan typically sits between 1.3 and 1.5, Brooklyn and Queens between 1.4 and 1.6, and the Bronx between 1.3 and 1.5.

Carriers do not publish their territory grids in full, and the filed rate pages on the NY Department of Financial Services website are drafted at a level of abstraction that does not resolve to an individual quote. This is why two OB/GYNs in the same specialty code, one practicing in Manhattan and one in Great Neck, can see a five-figure annual premium difference without any underlying risk-selection difference.

Why published numbers differ from actual paid premium

Published rate tables reflect filed base rates at a single limit and territory, before carrier-specific credits, schedule rating, claim-free discounts, and group or hospital endorsements. A MLMIC-insured internist in a multi-physician group with a clean ten-year claim history and a hospital-affiliated credit can pay 25–35% below the published base. A recent graduate with no claim history in a high-territory zone can pay 10–15% above the published base while the step factor matures. Use the table above to benchmark, not to forecast an exact quote.

NY payout data, 2015–2024

New York led the nation in 2024 with $550.12M in medical malpractice payouts across 1,205 National Practitioner Data Bank reports (Fiedler Deutsch / NPDB, 2024). Per-capita payout of $35.95 sits among the highest in the United States and has consistently exceeded the national median over the past decade (Diederich Healthcare, 2021 data, most recent per-capita published). The state's no-damage-caps regime and nuclear-verdict exposure, including a Westchester County $120M award on November 30, 2023 (Tyson & Mendes, 2023), drive the premium level.

The 2024 payout environment in context

The $550.12M aggregate and 1,205 reports in 2024 place New York at the top of every state ranking published by NPDB and the secondary analysts who compile the raw federal data. Average payout per report in NY works out to roughly $457,000, well above the national mean, a function of the state's jury practices, liberal venue rules, and the absence of cap legislation that has constrained payouts in Texas, California, and Florida since the 2000s.

Trend direction matters as much as level. NY payouts grew in each of the last three published years, which is what prompted Fiedler Deutsch's 2024 headline that the state now carries a 89.7% direct loss ratio, the highest among the ten largest MPL markets in the country. A loss ratio above 85% signals pricing pressure: absent continued rate increases, carriers retaining NY risk erode capital, which is one reason MLMIC's demutualization and Berkshire Hathaway's capital backing matter strategically.

Per-capita versus neighboring states

On a per-capita basis, NY's $35.95 payout per resident runs roughly three times the national median, and well above Massachusetts, Pennsylvania, and New Jersey. Those states carry their own high-payout reputations but sit in the $15–$25 per-capita range. The gap is driven by downstate verdicts, which dominate total dollars even though roughly half of NY physicians practice outside the five boroughs and Long Island. In practical terms, an upstate internist's rate still reflects downstate loss experience through the state-wide risk pool.

Nuclear verdicts: the Westchester $120M award

On November 30, 2023, a Westchester County jury returned a $120M verdict in a medical malpractice case, the largest in the county's history. The verdict is not typical, and we do not present it as representative. It is, however, the largest data point of the past five years and sits at the boundary of what NY claims-made policies can absorb before excess layers trigger. Physicians with $1M/$3M primary limits and a Section 18 or broker-sourced $1M/$3M excess have $2M total, which is a fraction of a verdict of this size. The plaintiff's collectability path in such cases typically runs through the primary carrier's bad-faith exposure for failure to settle within limits, which is why claims-decisions on settlement timing matter as much as limit selection.

Tail economics: the 1.5–2× rule

Tail coverage, technically an extended reporting endorsement, typically costs 150–200% of the most recent annual claims-made premium, paid as a single lump sum at policy termination. For a Manhattan OB/GYN at the top of the statewide base range, that translates to a mid-six-figure one-time check at retirement, job change, or specialty shift. The multiplier exists because the carrier must reserve for the entire long-tail reporting window with no future premium stream.

The 200% rule and its actual range

Industry-standard tail modeling uses a flat 200% multiplier, and that is the right ceiling to assume when planning. In actual NY quotes, the multiplier runs from about 150% for low-severity specialties with short reporting development, such as Psychiatry or Diagnostic Radiology in some carriers, up to the full 200% or slightly above for high-severity specialties, OB/GYN and Neurosurgery in particular. The span reflects each specialty's historical claim-development curve: claims that take longer to surface carry more uncertainty, and carriers price that uncertainty into the tail factor.

Who pays: employer, physician, or split

Tail responsibility is a contract term, not a coverage term. Three patterns are common in NY employment agreements. First, employer-paid tail, in which the practice or hospital funds the full buyout on termination. Second, physician-paid tail, in which the departing physician writes the check. Third, split tail, in which responsibility depends on who terminates and for what cause: an involuntary termination without cause, for example, triggers employer-paid tail, while a voluntary resignation triggers physician-paid tail.

A fourth pattern, the free tail provision, is becoming more common. It waives tail cost if termination follows retirement at age 55 or older with at least five years of continuous coverage, total permanent disability, or death. Physicians negotiating a new employment contract should push for a free-tail trigger on retirement and disability at minimum, because those are the two termination modes hardest to predict and most expensive to self-fund.

Strategic tail timing

Because tail is priced off the most recent annual premium, physicians approaching retirement can reduce the bill by stepping down scope of practice in the final year. An OB/GYN dropping obstetrics in year one of a two-year retirement wind-down may see annual premium fall by 35–50%, which proportionally lowers the tail. The arithmetic has to account for the year's premium and the tail together, because the carrier's final step rating applies in parallel, but for many physicians the scope reduction saves a meaningful share of the tail bill. The strategy only works with advance planning and an explicit carrier conversation about credential and scope documentation.

Primary care and internal medicine

Internal Medicine and Family Practice physicians without surgical privileges anchor New York's lowest-tier malpractice pricing, with statewide base rates in the ~$29K–$32K annual range at $1M/$3M claims-made limits and tail typically in the ~$55K–$65K range. Manhattan and Long Island add territory factors of 15–40%, while Rochester and much of the Southern Tier discount 50% or more against the downstate base. For a Family Practice physician in Buffalo, that can translate to an all-in premium in the low-to-mid teens annually.

Why primary care anchors the lowest tier

PCPs carry the lowest severity exposure of the common NY specialties. Internal Medicine and Family Practice without hospital admitting privileges have claim frequency in line with the statewide average, but claim severity, the average dollar value of a paid claim, runs well below surgical specialties because the alleged negligence pathways are limited. Missed or delayed diagnosis dominates PCP claims, and Lavern's Law's 7-year cancer discovery window now drives a disproportionate share of reserve reasoning for internists and family physicians.

Rate filings reflect this. MLMIC and EmPRO both price Internal Medicine without surgery at the same statewide base, and the carriers' territory modifiers narrow for PCPs compared to surgical specialties. The practical implication is that geographic arbitrage, relocating from Long Island to Westchester, for instance, offers less percentage savings for a PCP than for an OB/GYN.

Cost sub-table by territory and scope

Scope-of-practice premium swings

Scope changes move primary-care premium more than most physicians expect. Adding hospitalist admitting privileges increases base rate by roughly 40% because the hospital-patient severity distribution is higher. Adding minor office procedures (skin biopsies, joint injections, IUD placements) adds 10–15%. Adding moderate sedation or colonoscopy adds 25–40% and in some carriers reclassifies the physician out of the PCP code entirely.

The reverse holds on retirement wind-down: dropping hospital privileges a full policy year before retirement can reduce both the final annual premium and the tail it drives. For a Manhattan internist dropping hospitalist duties, the saved dollars can run well into five figures across the last premium year plus tail.

Concierge and direct primary care underwriting

Concierge practices and DPC (direct primary care) models sit in a slightly different underwriting bucket. MLMIC and EmPRO both write these models at roughly statewide PCP base rates, but the risk selection favors them: smaller panels, longer visits, and documented decision-making all reduce missed-diagnosis exposure. Underwriters will ask for panel size, visit duration, and procedure mix. Practices structured as professional entities with the physician as sole shareholder often qualify for single-physician rating, which can save 5–10% off group rating.

NY statute deep-dive: CPLR 214-a and Lavern's Law

CPLR § 214-a requires medical, dental, and podiatric malpractice actions to be commenced within 2 years and 6 months of the alleged act, omission, or the end of continuous treatment for the same illness, injury, or condition. Lavern's Law, the 2018 amendment, resets the clock on cancer and malignant-tumor misdiagnoses to the date of discovery, capped at 7 years from the alleged negligence. These two provisions, together with minors tolling and wrongful-death deadlines, define the long tail that NY malpractice carriers must reserve against.

The 2½-year baseline clock

CPLR 214-a reads, in relevant part, that an action for medical, dental, or podiatric malpractice "must be commenced within two years and six months of the act, omission or failure complained of or last treatment where there is continuous treatment for the same illness, injury or condition which gave rise to the said act, omission or failure." The continuous-treatment doctrine is the practical driver. A patient treated by the same physician or practice for an ongoing condition does not start the clock until the course of treatment ends, which in chronic-care settings can mean years of accumulated potential liability within a single limitation window.

New York's 2½ years is shorter than most states' 3-year medical-malpractice statute, but the continuous-treatment doctrine and Lavern's Law extensions effectively lengthen the real exposure. Carriers price NY risk against the effective exposure, not the statutory minimum. This gap between statute and reality is one of the most common sources of physician confusion when comparing NY premium against the rest of the country.

Lavern's Law: cancer discovery and the 7-year cap

Lavern's Law, enacted in 2018 and named for Lavern Wilkinson, amended CPLR 214-a to add a discovery rule for cancer and malignant-tumor misdiagnoses. Under the amendment, the 2½-year clock starts on the date the patient knew or reasonably should have known of the alleged negligence, rather than on the date of the act itself. The discovery-rule extension is capped at 7 years from the date of the alleged negligence.

The practical effect on retiring internists and radiologists is material. A physician retiring in 2026 who was still practicing in 2024 now faces a reporting window that extends to 2031 for a cancer claim. That means the tail coverage physicians of record need at retirement should be a 7-year reporting period, not the 5-year standard that many employment contracts default to. We continue to see NY retirement contracts written with 5-year tail language that will leave a 2-year coverage gap if a Lavern's Law claim surfaces in years 6 or 7.

The drafting fix is a two-line amendment: extend the tail reporting period to 7 years for physicians in specialties with cancer-diagnosis exposure, and reference CPLR 214-a discovery-rule language so future amendments to the statute track automatically. Physicians in radiology, internal medicine, dermatology, and primary care should insist on this language. Surgeons without diagnostic responsibility have lower exposure but still benefit from the longer window.

Minors tolling and wrongful death

For minors, the CPLR tolls the limitation period until the child reaches age 18, with a 10-year outside cap. A claim arising from obstetric or pediatric care can therefore be filed up to 10 years after the alleged negligence, or 2½ years after the child turns 18, whichever is earlier. This drives the reserve profile of OB/GYN and pediatric claims and is a principal reason those specialties price at 3–6× the PCP base rate.

Wrongful-death claims under EPTL 5-4.1 carry a separate 2-year limitation period from the date of death, which may extend the practical reporting window beyond the underlying malpractice limitation if death follows the negligence by more than 6 months. NY carriers reserve wrongful-death claims to the full 2-year-from-death window, which is the longest effective reporting tail for non-cancer physician specialties.

The combined effect of minors tolling, Lavern's Law, and wrongful-death extensions is that a single OB/GYN policy year can generate claim-reporting windows of up to 18 years when obstetric minors tolling applies. This is why the carrier's claim-reserve methodology, and the stability of its long-tail reserves, matter more for high-severity NY specialties than the headline annual premium does.

Switching carriers: retroactive dates and pitfalls

Retroactive date, the earliest date a claims-made policy will cover, is the single most important field on a carrier switch. A new carrier that refuses to honor the prior retro date leaves every patient encounter before the new policy's inception uninsured unless tail is purchased from the departing carrier. Physicians moving between MLMIC, EmPRO, and TDC should confirm continuous retro coverage in writing before binding. The Section 18 Excess program's reported 2024 closure has added complexity to switches that previously stacked state-funded excess layers.

Retro-date continuity

Continuous retro is the baseline ask on any carrier switch. The incoming carrier accepts the outgoing carrier's retroactive date, typically the physician's original date of NY licensure or practice start, and covers the full reporting window for past care. Pricing reflects the accepted retro: a physician with 15 years of retro coverage pays a mature step-factor premium from day one on the new carrier, not a fresh year-one rate.

MLMIC, EmPRO, and TDC all routinely accept continuous retro for clean-history physicians. The exception is a physician with a recent paid claim, an open reserve, or a disciplinary proceeding, which can cause the incoming carrier to limit the retro to the new policy's inception date. When that happens, the physician has three options: stay with the current carrier, buy tail from the departing carrier to cover the retro gap, or accept the limited retro and self-insure the gap, which is rarely advisable.

Tail from departing versus nose from new

When continuous retro is unavailable, the coverage gap for past care can be closed either by buying tail from the departing carrier or nose coverage from the new carrier. Tail is the extended reporting period on the old policy; nose is a prior-acts endorsement on the new policy. Economically, they serve the same purpose, but pricing and flexibility differ.

Tail from the departing carrier is priced at the carrier's standard tail multiplier (150–200%) and locks the reserve with a carrier the physician is already leaving. Nose from the new carrier is priced as a prior-acts credit folded into the new annual premium over several years, which spreads the cost but extends the commitment. Most physicians choose tail when they are confident in the departing carrier's long-term solvency and nose when they want to simplify administration and are comfortable paying over time.

Three common NY switching mistakes

We have seen three recurring errors when NY physicians switch carriers. First, binding the new policy before receiving a written confirmation of retro acceptance, which creates a gap if the new carrier later limits the retro. Second, letting the departing policy lapse for a day or more between the old policy's termination and the new policy's inception, which voids the retro continuity entirely. Third, failing to confirm whether any open claim at the departing carrier will travel with the physician's claims history to the new carrier, which can affect underwriting and future premium.

The cleanest switch sequence is: obtain written retro confirmation from the incoming carrier referencing the specific retro date, bind the new policy with an effective date one minute after the departing policy's expiration, confirm in writing with the departing carrier that the policy is terminating (not cancelling, which is a distinct notation on the carrier's claims-history report), and file the retro-continuity confirmation in the physician's personal credentialing file. None of these steps costs money. All three prevent the most expensive coverage mistakes we see in practice.

Borough-level rate variance

Territory factors produce a roughly 5× spread on the same specialty code in New York. An OB/GYN premium at $1M/$3M claims-made limits can run from the mid-$30Ks in Rochester to nearly $200K on Long Island. Manhattan typically sits between Brooklyn/Queens and the Long Island premium, which has the state's highest territory modifier because of Nassau and Suffolk County verdict history. Upstate zones, particularly Rochester and the Southern Tier, discount 50% or more from the downstate base.

Territory factor comparison across carriers

Territory factors differ meaningfully across NY's three largest MPL carriers, which is why two brokers quoting the same physician in the same zip code can produce different numbers. MLMIC's territory grid divides the state into six zones, with Long Island at the top end. EmPRO uses a more granular grid that breaks Brooklyn and Queens into separate factors, which can advantage Queens-based physicians relative to MLMIC's consolidated downstate factor. TDC applies a national rating model adjusted for NY filings, and for multi-state physicians its factor grid often produces the most competitive Manhattan quote.

Published filings on the NY Department of Financial Services rate database resolve to zones but not to the full carrier-specific modifier stack. A physician benchmarking premium against published tables will understate the variance between carriers in a downstate zone by 10–20% in our experience. A multi-carrier quote comparison, not a single published rate, is what produces a realistic view of actual paid premium.

Why Long Island prices above Manhattan

Long Island's Nassau and Suffolk county zone carries the state's highest territory modifier, higher even than Manhattan or Brooklyn. The driver is jury-verdict history, specifically the concentration of nuclear verdicts in Nassau County Supreme Court over the past decade. Manhattan's verdict distribution is broader but more moderated, producing a lower average severity per paid claim despite higher total dollars.

For a physician deciding between a Great Neck practice and a Manhattan practice, the malpractice premium delta alone can exceed $20,000 annually on an OB/GYN book. That number is material in a compensation negotiation, and physicians weighing the two options should model the all-in premium across a 5-year employment horizon, not just the first year. Employment contracts that net out malpractice premium before calculating physician compensation are common on Long Island, and understanding the territory-factor math before signing is the only way to see what the offer actually pays.

Upstate discount zones

Rochester, Syracuse, Buffalo, and the Southern Tier all sit at territory factors of 0.5–0.7 relative to the downstate base. For most specialties, moving from a downstate zone to Rochester reduces malpractice premium by 55–70% and reduces tail at retirement by the same percentage because tail is calculated off the final annual premium. The dollar savings for a high-severity specialty can fund a meaningful share of a retirement plan over a 20-year career.

The counterpoint is that upstate compensation is typically lower, and the combined effect on real net income varies by specialty and practice model. Physicians weighing the geographic arbitrage should model the full compensation and premium picture, including tail, and not just premium in isolation. The wrong framing, premium alone or compensation alone, produces the wrong decision in both directions roughly as often as it produces the right one.

Borough-by-borough quick reference

Within New York City, Manhattan sits mid-pack on territory factor for most specialties, with Brooklyn and Queens above it and the Bronx below. This surprises physicians who assume Manhattan must be the most expensive zone in the state. It is not: Long Island is, driven by Nassau County verdict history, and Brooklyn frequently prices above Manhattan because of Kings County jury composition. Queens runs between Brooklyn and Manhattan on most specialty codes, with more favorable factors in EmPRO's granular grid than in MLMIC's consolidated downstate factor.

The borough factor is layered on top of the specialty base and any scope-of-practice modifier, which means a Brooklyn internist adding hospitalist duties and a Long Island OB/GYN practicing in an ambulatory surgery center see compounding effects that a flat published rate table cannot capture. Whenever a physician considers a move between boroughs, pulling an actual quote in the new zip code, not extrapolating from the territory factor, is the only reliable way to forecast the all-in number.

For deeper specialty-specific context on the borough analysis above, review our companion pieces on OB/GYN malpractice rates across NY, orthopedic surgery coverage for NY specialists, general surgery malpractice pricing in New York, plastic surgery cosmetic-vs-reconstructive rating, and NY dental malpractice coverage for DDS and DMD practices. For a carrier-level comparison, our analysis of the best NY medical malpractice insurance options for physicians walks through the trade-offs that this guide summarizes. Readers weighing retirement or job change should also see our detailed treatment of when tail coverage is required and how to price it and occurrence versus claims-made structures in NY. Service-level information lives on the professional liability coverage page and industry context sits on the physicians industry page.

Talk to a broker before you bind

New York's malpractice market rewards precision: the right carrier, the right retro date, the right tail structure, and the right territory rating can move a physician's career cost of coverage by six figures. If your renewal is within 90 days, a carrier switch is on the table, or you are negotiating a new employment contract with tail language, a 30-minute conversation with a broker appointed across MLMIC, EmPRO, and The Doctors Company is usually the highest-leverage hour in the process. You can request a quote or schedule a consultation when you are ready.